Hoffmann-La Roche Ltd (Switzerland) and Johnson & Johnson Services, Inc. (US) are Leading Players in the Monoclonal Antibody (mABs) Therapeutics Market
The monoclonal antibody therapeutics market is projected to reach USD 497.5 billion by 2029 from an estimated USD 252.6 billion in 2024, at a CAGR of 14.5% during the forecast period. The major factors driving the growth of this monoclonal antibody therapeutics market include increasing prevalence of chronic diseases, advancements in biotechnology, growing investment in R&D, rising demand for targeted therapies, expanding applications in cancer and autoimmune diseases, and favorable regulatory initiatives fostering innovation and market expansion.
The global monoclonal antibody therapeutics market is consolidated with top players such Hoffmann-La Roche Ltd (Switzerland), Abbvie Inc. (US), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Sanofi (France). The market players have adopted various strategies such as new product launches, acquisitions, agreements, collaborations, partnerships, and geographical expansions to strengthen their position in the global monoclonal antibody therapeutics market.
To know about the assumptions considered for the study download the pdf brochure
Hoffmann-La Roche Ltd (Switzerland)
F. Hoffmann-La Roche AG stands at the forefront of the monoclonal antibody therapeutics market, leveraging a robust strategy anchored in innovation and strategic partnerships. With a global footprint spanning major pharmaceutical markets, including the US, Europe, and Asia, Roche maintains a significant presence. Their success lies in a diverse portfolio of monoclonal antibody therapies targeting various diseases, bolstered by a relentless commitment to research and development. Additionally, Roche's focus on personalized medicine and biomarker-driven approaches enhances treatment efficacy. Continual investment in cutting-edge technologies and a deep understanding of patient needs further solidifies Roche's position as a leader in the field. The company additionally focuses on product launches and investment in clinical trials as well. For instance, in February 2024, Roche’s subsidiary Chugai Pharmaceutical, developed crovalimab and owns its rights in Japan and Taiwan, received the approval of the humanized complement inhibitor C5 monoclonal antibody. China’s National Medical Products Administration (NMPA) also permitted its use in patients age 12 and older who have not received complement inhibitor therapy.
Johnson & Johnson Services, Inc. (US)
Johnson & Johnson (J&J) commands a prominent position in the monoclonal antibody therapeutics market with a multifaceted approach. Their strategy encompasses strategic launches of innovative therapies, bolstered by collaborations with academia and industry partners. Geographically, J&J maintains a global presence, with operations spanning key pharmaceutical markets worldwide. Their success is underpinned by a diverse pipeline of monoclonal antibody products targeting various diseases. Moreover, J&J's emphasis on research and development, coupled with a commitment to addressing unmet medical needs, strengthens their competitive edge. For instance, in August 2023, the Janssen Pharmaceutical Companies of Johnson & Johnson announced received FDA approval for TALVEY (talquetamab-tgvs) a first-in-class bispecific antibody for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Through continual innovation and strategic alliances, J&J remains a formidable player in advancing monoclonal antibody therapeutics.
Related Reports:
Monoclonal Antibody (mABs) Therapeutics Market by Production Method (In-Vitro, In-Vivo), Sources (Human, Chimeric), Route of Administration (Intravenous, Subcutaneous), Therapy (Inflammatory & Autoimmune, Oncology, Hematology) - Global Forecast to 2029
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
